Increased intracellular cAMP renders HL-60 cells resistant to cytotoxicity of taxol

Immunopharmacology and Immunotoxicology

Volumn 21, Issue 2, 1999, Pages 233-245

  Pae, Hyun Ock ^a,b   Yoo, Ji Chang ^a   Jun, Chang Duk ^a   Paik, Sang Gi ^b   Choi, Byung Min ^a   Baek, Kang Ho ^a   Kim, Jong Moon ^a   Chung, Hun Taeg ^a  

^a Wonkwang University   (South Korea)

^b Chungnam National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

8 (4 CHLOROPHENYLTHIO) CYCLIC AMP; 8 BROMO CYCLIC AMP; BUCLADESINE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; DIMETHYL SULFOXIDE; FORSKOLIN; KT 5720; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PACLITAXEL; RETINOIC ACID; TUBULIN;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; CANCER CHEMOTHERAPY; CELL DEATH; CELL MUTANT; CYTOTOXICITY; DOSE RESPONSE; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

EID: 0032890844     PISSN: 08923973     EISSN: None     Source Type: Journal    
DOI: 10.3109/08923979909052760     Document Type: Article

References (20)

1. McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partidge, E. E., Look, K. Y., Clarrke-Pearson, D. L. & Davidson, M., Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer, N. Engl. J. Med., 334:1, 1996.
2. Holmes, F. A., Walters, R. S., Therialault, R. L., Forman, A. D., Newton, L. K., Raber, M. N., Buzdar, A. U., Frye, D. K. & Hortobagyi, G. N., Phase II trail of taxol, an active drug in the treatment of metastatic breast cancer, J. Natl. Cancer Inst., 83: 1797, 1991.
3. Murphy, W. K., Fossella, F. V., Winn, R. J., Shin, D. M., Hynes, H. E., Gross, H. M., Davilla, E., Leimert, J., Dhingra, H. & Raber, N. M., Phase II trial of taxol in patients with untreated advanced non-small-cell lung cancer, J. Natl. Cancer Inst., 85:384, 1993.
4. Horwitz, S. B., Chohen, D., Rao, S., Ringel, I., Shen, H. J. & Yang, C. P., Taxol : mechanisms of action and resistance. J. Natl. Cancer Inst. Monogr., 15:55, 1993.
5. Wani, M. C., Taylor, H. L., Wall, M. E., Coggon, P. & McPhail, A. T., Plant antitumor agents VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from taxus brevifolia, J. Am. Chem. Soc., 93:2325, 1971.
6. Schiff, P. B. & Horwitz, S. B., Taxol stabilizes microtubules in mouse fibroblast cells, Proc. Natl. Acad. Sci. U. S. A., 77:1561, 1980.
7. Rao, S., Orr, G. A., Chaudhary, A. G., Kingston, D. G. I. & Horwitz, S. B., Characterization of the taxol binding site on the microtubule, J. Biol. Chem., 270:20235, 1995.
8. Derry, W. B., Wilson, L. & Jordan, M. A., Substoichiometric binding of taxol suppresses microtubule dynamics, Biochemistry, 34:2203, 1995.
9. Jordan, M. A., Toso, R. J., Thrower, D. & wilson, L., Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations, Proc. Natl. Acad. Sci. U. S. A., 90:9552, 1993.
10. Roy, S. N. & Horwitz, S. B., A phosphoglycoprotein associated with taxol resistance in J774.2 cells, Cancer Res., 45:3856, 1985.
11. Greenberger, L. M., Lothestein, L., Williams, S. S. & Horwitz, S. B. H., Distinct P-glycoprotein precursors are overproduced in independently isolated drug-resistant cell lines, Proc. Natl. Acad. Sci. U. S. A., 85:3762, 1988.
12. Kuo, D. Y. S., Mallick, S., Shen, H. J., DeVictoria, C., Jones, J., Fields, A. L., Goldberg, G. L., Runowicz, C. D. & Horwitz, S. B., Analysis of MDR1 expression in normal and malignant endometrium by reverse transcription-polymerase chain reaction and immunohistochemistry, J. Clin. Cancer Res., 2:1981, 1996.
13. Noonan, K. E., Beck, C., Holzmayer, T. A., Chin, J. E., Wunder, J. S., Andrulis, I. L., Gazdar, A. F., Willman, C. L., Grifith, B., Von Hof, D. D. & Roninson, I. B., Quantitative analysis of MDR1 (multidrug resistant) gene expression in human tumors by polymerase chain reaction, Proc. Natl. Acad. Sci. U. S. A., 87:7160, 1990.
14. Jaffrezou, J. P., Dumontet, C., Derry, W. B., Duran, G., Chen, G., Tsuchiya, E., Wilson, L., Jordan, M. A. & Sikic, B. L., Novel mechanism of resistance to paclitaxel (taxol) in human K562 leukemia cells by combined selection with PSC 833, Oncol. Res., 7:517, 1995.
15. Bordow, S. B., Haber, M., Madafiglio, J., Cheung, B., Marshall, G. M. & Norris, M. D., Expression of the multigrug resistance-associated protein (MRP) gene correlates with amplification and overexpression of the N-myc oncogene in chidhood neuroblastoma, Cancer Res. 54:5036, 1994.
16. Parekh, Wiesen, H., K. & Simpkins, K., Acquisition of taxol resistance via P-glycoprotein-and non-P-glycoprotein-mediated mechanisms in human ovarian carcinoma cells, Biochem. Pharmacol., 53(4):461, 1997.
17. Ratnasinghe, D., Phang, J. M. & Yeh, G. C., Differential expression and activity of phosphatases and protein kinases in adriamycin sensitive and resistant human breast cancer MCF-7 cells, Int. J. Oncol., 13(1):79, 1998.
18. Savickiene, J., Gineitis, A., Shanbhag, V. P. & Stigbrand, T., Relationship between differentiation mechanisms involving cAMP-dependent protein kinase and protein kinase C in uninduced and differentiating HL-60 cells, Anticancer Res., 17(1A):285, 1997.
19. Olsson, I. L., Breitman, T. R. & Gallo, R. C., Priming of human myeloid leukemic cell lines HL-60 and U-937 with retinoic acid for differentiation effects of cyclic adenosine 3′:5′-monophosphate-inducing agents and a T-lymphocyte-derived differentiation factor, Cancer Res., 42(10):3928, 1982.
20. Cvijic, M. E., Yang, W. L. & Chin, K. V., Cisplatin resistance in cyclic AMP-dependent protein kinase mutants, Pharmacol. Ther., 78(2):115, 1998.